相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
Mark Clemons et al.
EUROPEAN JOURNAL OF CANCER (2021)
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
Terry L. Ng et al.
SUPPORTIVE CARE IN CANCER (2021)
Two-year results of a randomised trial comparing 4-versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
Mark Clemons et al.
JOURNAL OF BONE ONCOLOGY (2021)
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate
Hirotaka Miyashita et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Breast Cancer, Version 3.2020
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis
Arif Ali Awan et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ten-year experience of the multidisciplinary Osteoncology Center
Alberto Bongiovanni et al.
SUPPORTIVE CARE IN CANCER (2019)
Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States
Rohini K. Hernandez et al.
BMC CANCER (2018)
1552TiPPREVENTION OF SYMPTOMATIC SKELETAL EVENTS WITH DENOSUMAB ADMINISTERED EVERY 4 WEEKS VERSUS EVERY 12 WEEKS–A NON-INFERIORITY PHASE III TRIAL: SAKK 96/12 - REDUSE
A.J. Templeton et al.
ANNALS OF ONCOLOGY (2017)
Bisphosphonates and other bone agents for breast cancer
B. O'Carrigan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
De-escalation of bone-targeted agents for metastatic prostate cancer
Brian Younho Hong et al.
CURRENT ONCOLOGY (2016)
Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis
Arif Hussain et al.
CANCER MEDICINE (2016)
Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)
Ricardo Fernandes et al.
JOURNAL OF BONE ONCOLOGY (2016)
A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
C. L. Addison et al.
JOURNAL OF BONE ONCOLOGY (2016)
Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis
M. F. K. Ibrahim et al.
ANNALS OF ONCOLOGY (2015)
Survival with Newly Diagnosed Metastatic Prostate Cancer in the Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James et al.
EUROPEAN UROLOGY (2015)
Dosing Strategies of Bone-Targeting Agents
Brian Hutton et al.
JAMA INTERNAL MEDICINE (2015)
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
Christina L. Addison et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival
Christian B. van der Pol et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Pharmacotherapy of bone metastases in breast cancer patients - an update
Carmel Jacobs et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
Christina L. Addison et al.
SPRINGERPLUS (2014)
Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer
Eitan Amir et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study
Adam M. Brufsky et al.
BREAST JOURNAL (2013)
Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid
Charles S. Cleeland et al.
CANCER (2013)
Incidence, consequences and treatment of bone metastases in breast cancer patients Experience from a single cancer centre
I. Kuchuk et al.
JOURNAL OF BONE ONCOLOGY (2013)
Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
Iryna Kuchuk et al.
JOURNAL OF BONE ONCOLOGY (2013)
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid
Henry Henk et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art
M. Clemons et al.
CURRENT ONCOLOGY (2012)
Treatment Persistence With Monthly Zoledronic Acid is Associated With Lower Risk and Frequency of Skeletal Complications in Patients With Breast Cancer and Bone Metastasis
Hind T. Hatoum et al.
CLINICAL BREAST CANCER (2011)
Bisphosphonates as Treatment of Bone Metastases
Ingunn Holen et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Pattern of metastatic spread in triple-negative breast cancer
Rebecca Dent et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years
V Guarneri et al.
ONCOLOGIST (2005)
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer
W Liauw et al.
BMC CANCER (2005)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints
PP Major et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
分享论文
